Iberdomide

Iberdomide (CC-220) is Bristol Myers Squibb's next-generation cereblon E3 ligase modulator. It is a 'molecular glue' pill that hijacks the cell's own protein disposal system to destroy two transcription factors, Ikaros and Aiolos, that multiple myeloma cells depend on to survive. It is the successor molecule to lenalidomide (Revlimid) and pomalidomide (Pomalyst), both of which work through the same cereblon protein but less efficiently. Revlimid alone peaked at roughly $12.8 billion in annual revenue in 2021; combined with Pomalyst at approximately $3.5 billion, the legacy CELMoD franchise generated approximately $16 billion at peak for Celgene and then BMS [12]. The registrational Phase 3 trial EXCALIBER-RRMM tests iberdomide plus daratumumab and dexamethasone against daratumumab, bortezomib, and dexamethasone in relapsed or refractory patients [1][2]. BMS submitted the NDA on the basis of minimal residual disease (MRD) negativity data, the FDA accepted it under Priority Review with a PDUFA action date of August 17, 2026, and granted Breakthrough Therapy Designation [3]. As of today (2026-07-28) the FDA decision is roughly three weeks away. Results matter because BMS needs to defend the IMiD/CELMoD franchise as Revlimid revenue erodes under generic competition and BCMA-directed bispecifics and CAR-Ts push into earlier lines of treatment.

Iberdomide is a novel compound, never approved anywhere. BMS filed the NDA and the FDA accepted it under Priority Review with a PDUFA action date of August 17, 2026, and granted Breakthrough Therapy Designation for the iberdomide + daratumumab + dexamethasone (IberDd) combination [3]. If cleared, this is iberdomide's first approval. The NDA package leans on MRD negativity rates (a measure of how deeply the drug clears cancer cells below the detection limit of standard bone marrow tests) from a pre-planned analysis of EXCALIBER-RRMM, with progression-free survival (PFS) still the confirmatory readout. Development extends well beyond second-line RRMM. EXCALIBER-Maintenance is a separate Phase 3 comparing single-agent iberdomide against lenalidomide as maintenance after autologous stem cell transplant (ASCT - a procedure where patients receive high-dose chemotherapy, then get their own previously collected stem cells reinfused to rebuild their immune system) in newly diagnosed patients, a direct swing at Revlimid's remaining stronghold [4]. Academic groups are running Phase 2 combinations including the ICON study of iberdomide plus low-dose cyclophosphamide and dexamethasone in relapsed or refractory disease [5]. Beyond myeloma, iberdomide has run through Phase 2 in systemic lupus erythematosus, though BMS has deprioritized that program and pushed harder on myeloma [6]. Companion programs in non-Hodgkin lymphoma (with R-CHOP, and with the CD20 bispecifics mosunetuzumab and glofitamab) sit in Phase 1 [7]. Orphan Drug Designation status was not confirmed in public search; multiple myeloma qualifies as an orphan indication so ODD is likely held but not verified here. One data note: several public listings for this node still point to a small investigator-initiated trial (NCT05434689) rather than the BMS-sponsored registrational program NCT04975997.

CELMoDs are molecular glues. They bind cereblon (CRBN), a protein that acts as the address book of a machine called the CRL4 E3 ubiquitin ligase. That machine tags other proteins with a chemical label (ubiquitin) that marks them for destruction by the proteasome, the cell's shredder. On its own, cereblon has a handful of natural substrates. When a CELMoD sits in its binding pocket, it reshapes cereblon so it grabs Ikaros (IKZF1) and Aiolos (IKZF3), two transcription factors that plasma cells need to survive and produce antibodies. Once tagged, both proteins get shredded. Myeloma cells, which are cancerous plasma cells, die. As a bonus, degrading Aiolos in T cells and NK cells lifts a brake on those immune cells, adding an anti-tumor immune response on top of the direct kill. This mechanism is well-validated. Lenalidomide and pomalidomide (originally called IMiDs, now retroactively lumped into the CELMoD family) have generated tens of billions in revenue in myeloma. Iberdomide binds cereblon substantially more tightly than lenalidomide and drives deeper, faster degradation of Ikaros and Aiolos in preclinical models and in patient plasma cells [8]. The commercial bet: better molecular pharmacology translates to better clinical response in patients whose disease has already learned to tolerate the older drugs.

EXCALIBER-RRMM (NCT04975997) is a randomized open-label Phase 3 comparing iberdomide plus daratumumab plus dexamethasone (IberDd) against daratumumab plus bortezomib plus dexamethasone (DVd) in adults with relapsed or refractory multiple myeloma after one to three prior lines including lenalidomide [1][2]. The protocol-defined primary endpoint is investigator-assessed progression-free survival (PFS). Enrollment target is roughly 660 patients across sites in North America, Europe, and Asia-Pacific. BMS has stated the trial completed enrollment. The NDA package, however, is anchored on a pre-planned analysis of MRD negativity rates (the fraction of patients whose bone marrow shows no detectable cancer cells at very high sensitivity), with mature PFS to follow as confirmation [3]. Comparator strength matters here: DVd is a well-established second-line regimen with PFS in the 16 to 18 month range depending on the population. To register with any commercial momentum, IberDd needs a clear MRD-negativity advantage now and a clean PFS win at maturity, not just non-inferiority. A second registrational Phase 3, EXCALIBER-Maintenance, tests iberdomide monotherapy against lenalidomide monotherapy as maintenance post-ASCT in newly diagnosed patients, powered on PFS with a larger patient count [4]. Data quality note: the NCT ID stored on this node (NCT05434689) is a small University of Alabama at Birmingham investigator-initiated MRD-eradication study, not the BMS registrational trial. The trial actually driving Phase 3 status is NCT04975997.

This drug is under FDA review (NDA/BLA), with a PDUFA decision date of 2026-08-17. Our estimate of 88% is the historical filing-approval rate for its area, adjusted for its rejection history (no prior Complete Response Letters). At this stage the early-trial design model no longer applies - what matters is that it reached the FDA and whether it has been rejected before.

Four buckets. Efficacy: even with MRD negativity anchoring the NDA, EXCALIBER-RRMM needs a clean PFS win over DVd at maturity. If the PFS delta is under four to six months, payers and clinicians will question whether iberdomide is meaningfully better than swapping in generic pomalidomide with the same anti-CD38 backbone. The CC-220-MM-001 monotherapy plus dexamethasone ORR was 26.2% in triple-class refractory patients (defined as patients whose cancer has stopped responding to all three main myeloma drug classes: proteasome inhibitors, IMiDs/CELMoDs, and anti-CD38 antibodies) [10]. Respectable but not dazzling, so combination data has to carry the story. Median PFS in that same monotherapy cohort was in the 3 to 4 month range, so the Phase 3 combination has real work to do to reach the mid-teens. Safety: neutropenia is the dominant dose-limiting toxicity, matching the class. Manageable with dose modification but a real barrier in triplet and quadruplet combinations. Class-wide there is also a long-standing signal for secondary primary malignancies with prolonged IMiD exposure, which will get scrutinized in the maintenance study. Competition: BCMA (B-cell maturation antigen, a protein on myeloma cell surfaces targeted by a newer class of antibody-based drugs and cell therapies) directed teclistamab, elranatamab, cilta-cel, and ide-cel are pulling patients earlier in the sequence, shrinking iberdomide's addressable market on the back end. Mezigdomide (CC-92480), BMS's own next-generation CELMoD, showed 40.6% ORR in triple-class refractory patients with dexamethasone in the CC-92480-MM-001 Phase 1/2 [11] and could become the internal successor before iberdomide is fully commercialized. Commercial: pricing an oral branded CELMoD against generic lenalidomide requires clear efficacy differentiation. In the maintenance setting especially, replacing a cheap generic with a branded newer molecule is a payer conversation, not a slam dunk.

Worth watching, actively. The FDA decision is imminent: PDUFA is August 17, 2026 [3], approximately three weeks from the date of this writeup (2026-07-28). Breakthrough Therapy Designation plus Priority Review plus MRD-negativity-based filing means base-case approval is likely, and the next binary catalyst is whether the label is broad (post-lenalidomide 2L+) or narrow (specific line/prior-therapy language) and whether any REMS or boxed warning language surfaces. The 2L+ RRMM market in the US is roughly 15,000 to 20,000 eligible patients per year based on SEER incidence and standard progression assumptions, feeding into a Darzalex-backboned combination market already north of $6 billion annually. Analyst peak sales estimates for iberdomide have clustered in the $2 to $3 billion range if BMS holds durable share against generic pomalidomide combos. Launch readiness watch: BMS has not publicly named a WAC price and reimbursement pathway details are not yet disclosed; both should surface at or shortly after PDUFA. If IberDd goes on to beat DVd on mature PFS by six months or more in the intent-to-treat population, iberdomide gets a durable second-line franchise and BMS buys itself another decade of CELMoD revenue against the Revlimid patent cliff. If the delta is marginal, the drug approves but sits in a crowded pocket while mezigdomide takes the future. Immediate checkpoints: the PDUFA decision itself in August, ASH 2026 for late-breaking EXCALIBER-RRMM subgroup and mature PFS data plus updated mezigdomide readouts, and BMS's Q3 to Q4 earnings calls where management will preview launch positioning and pricing. For BMS this is a defensive-plus-growth play, extending the IMiD/CELMoD franchise while the company pivots capital toward BCMA bispecifics and cell therapy.